Evidence map›Paper›PMID 35680632›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2022

[Analysis of the effect of gene mutations on the efficacy of ruxolitinib in patients with myelofibrosis based on second-generation sequencing technology].

Y X Tan, J Luo, J X Huang, D M Luo, H Y Liang, X Zhou, X L Liu, N Xu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Y X TanDepartment of Hematology, Nan fang Hospital, Southern Medical University, Guangzhou 510515, China.
J LuoDepartment of Hematology, Nan fang Hospital, Southern Medical University, Guangzhou 510515, China.
J X HuangDepartment of Hematology, Yuebei People's Hospital, Shaoguan 512025, China.
D M LuoDepartment of Hematology, Nan fang Hospital, Southern Medical University, Guangzhou 510515, China.
H Y LiangDepartment of Hematology, Nan fang Hospital, Southern Medical University, Guangzhou 510515, China.
X ZhouDepartment of Hematology, Nan fang Hospital, Southern Medical University, Guangzhou 510515, China.
X L LiuDepartment of Hematology, Nan fang Hospital, Southern Medical University, Guangzhou 510515, China.
N XuDepartment of Hematology, Nan fang Hospital, Southern Medical University, Guangzhou 510515, China.
Southern Medical University · CNShantou University · CN

Funding

National Natural Science Foundation of China 81700104Natural Science Foundation of Guangdong Province 2019A043135067Science and Technology Program of Guangzhou City 201904010488
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Primary MyelofibrosisHumansMutationNitrilesPyrazolesPyrimidinesRetrospective StudiesTechnologyTranscription FactorsNitrilesPyrazolesPyrimidinesruxolitinibTranscription FactorsDriver mutationMyelofibrosisNext-generation sequencingRuxolitinib

Identifiers

PMID35680632
PMCPMC9189480
OpenAlexW4282925367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.